intra-procedural intracardiac echocardiography
Deviceuse of intra-procedural intracardiac echocardiography during Watchman FLX devices
Other names: Watchman FLX Device
NCT Number: NCT04196335
The primary objective of this study is to assess the efficacy and safety of using intra-procedural intracardiac echocardiography (ICE) for WATCHMAN FLX Device implants in subjects with non-valvular atrial fibrillation to reduce the risk of stroke.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aarhus Universitetshospital, Skejby, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
use of intra-procedural intracardiac echocardiography during Watchman FLX devices
Other names: Watchman FLX Device
Time frame: 45 days
Rate of significant leak (>5 mm) as assessed by TEE at 45 days' post-implant.
Boston Scientific Corporation
Industry
Acronym: ICELAA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05523908
Efficacy, Self, Safety Issues
Hefei, Anhui, China
View Trial DetailsNCT04561466
Efficacy, Self, Safety Issues
Paris, France
View Trial DetailsNCT05164263
Diabetes Mellitus, Diabetes Mellitus, Type 2
Kabul, Afghanistan
View Trial DetailsNCT04861506
Cardiovascular Diseases, Efficacy, Self
Hangzhou, Zhejiang, China
View Trial Details